RNA

Total RNA was prepared from cell line WM88. WM88 is a tumorigenic primary melanoma cell line with competence for metastasis. These cells display melanocytic morphology in culture. This cell line was established from a metastatic site in a male patient with level III superficial spreading melanoma with tumor thickness of 0.92. This cell line contains the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. The cells are wild type for PTEN, N-ras, c-KIT and CDK4. WM88 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM9. DNA was prepared from cell line WM9. WM9 is a human metastatic melanoma cell line that was established from a metastatic site (left axillary node) in a male patient. This cell line features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM9 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM9. DNA was prepared from cell line WM9. WM9 is a human metastatic melanoma cell line that was established from a metastatic site (left axillary node) in a male patient. This cell line features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM9 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM9. DNA was prepared from cell line WM9. WM9 is a human metastatic melanoma cell line that was established from a metastatic site (left axillary node) in a male patient. This cell line features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN hemizygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM9 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM902B. WM902B is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and R24L mutation at position 24 in the CDK4 gene. The R24L mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to Leucine (L). This mutation renders the protein resistant to the inhibitory effects of INK4A function. WM902B cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM902B. WM902B is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and R24L mutation at position 24 in the CDK4 gene. The R24L mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to Leucine (L). This mutation renders the protein resistant to the inhibitory effects of INK4A function. WM902B cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM902B. WM902B is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and R24L mutation at position 24 in the CDK4 gene. The R24L mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to Leucine (L). This mutation renders the protein resistant to the inhibitory effects of INK4A function. WM902B cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM983A. WM983A is a VGP human malignant metastatic melanoma cell line that features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line is wild type for PTEN, N-RAS, c-KIT, and CDK4. This cell line was derived from the same patient as the cell lines WM983B, WM983B BR and WM983C.WM983A cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM983A. WM983A is a VGP human malignant metastatic melanoma cell line that features the V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line is wild type for PTEN, N-RAS, c-KIT, and CDK4. This cell line was derived from the same patient as the cell lines WM983B, WM983B BR and WM983C.WM983A cells produce xenograft tumors when injected into immunocompromised mice.